⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 4, 2025Open Access

Supplementary Figure S7 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors

Min Wang Yanxing Chen Lin Tian Chenyi Wu Jiaying Chen Jiajia Hu Runjie Huang Yingnan Wang Jinling Zhang Xiaojun Ouyang Liqin Wang Ying Jin Qi Zhao Feng Wang Rui‐Hua Xu

View Full Paper

Ask AI

Bookmark

Share

Key Points

Combining hdac inhibitors with immunotherapy improves antitumor efficacy in solid tumors.
The treatment resulted in increased immune cell infiltration and functionality in patient samples.
The approach leverages anti-angiogenesis therapy to enhance the immune response against tumors.
These findings point to a promising strategy for enhancing cancer treatment effectiveness.

Implication

Combined hdac inhibitors and anti-angiogenesis therapy improved immune cells infiltration in solid tumors, suggesting enhanced efficacy.

Abstract

Combined HDAC inhibitor, anti-angiogenesis therapy with immunotherapy hastens the immune cells infiltration and functionality in patient sample

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/68c18c089b7b07f3a06148de https://doi.org/10.1158/2159-8290.30050793

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S6 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors2025
2Supplementary Figure S3 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors2025
3Supplementary Figure S5 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors2025
4Supplementary Figure S2 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors2025
5Supplementary Figure S9 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors2025

More related papers

Supplementary Figure S1 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors2025
Supplementary Figure S8 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors2025
Supplementary Figure S4 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors2025